Navidea Biopharmaceuticals, Inc. Common Stock (NY:NAVB)

N/A UNCHANGED

Last Price Updated: 8:00 PM EDT, Oct 5, 2023 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Navidea Biopharmaceuticals, Inc. Common Stock

< Previous 1 2 3 4 5 6 Next >

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

March 14, 2023

Via Benzinga

12 Health Care Stocks Moving In Monday's After-Market Session ↗

March 13, 2023

Via Benzinga

Why Horizon Global Shares Are Trading Higher By Over 340%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

January 03, 2023

Gainers Horizon Global Corporation (NYSE: HZN) shares surged 341% to $1.7161 after the company announced it will be acquired by First Brands Group.

Via Benzinga

Navidea Biopharmaceuticals Announces the Notice of Allowance for U.S. Patent Application for Key Component of the Company’s Cancer Immunotherapy Pipeline

January 03, 2023

From Navidea Biopharmaceuticals, Inc.

Via Business Wire

Why Silo Pharma Shares Are Trading Higher By Around 64%? Here Are 46 Stocks Moving In Friday's Mid-Day Session ↗

December 30, 2022

Gainers Dermata Therapeutics, Inc. (NASDAQ: DRMA) shares jumped 121% to $0.4428 after the company requested to withdraw its registration on Form S-1 and said it does not intend to pursue the...

Via Benzinga

Navidea Biopharmaceuticals Files Appeal in CRG Case

November 30, 2022

From Navidea Biopharmaceuticals, Inc.

Via Business Wire

Navidea Biopharmaceuticals Announces 50th Participant Enrolled in the Company’s Phase 3 Trial in Rheumatoid Arthritis

November 28, 2022

From Navidea Biopharmaceuticals, Inc.

Via Business Wire

CORRECTING and REPLACING Navidea Biopharmaceuticals Reports Third Quarter 2022 Financial Results

November 14, 2022

From Navidea Biopharmaceuticals, Inc.

Via Business Wire

Navidea Biopharmaceuticals Announces Details of Presentation at Upcoming Society for Immunotherapy of Cancer Annual Meeting

November 07, 2022

From Navidea Biopharmaceuticals, Inc.

Via Business Wire

Stocks That Hit 52-Week Lows On Friday ↗

November 04, 2022

Friday's session saw 236 companies set new 52-week lows.

Via Benzinga

Navidea Biopharmaceuticals to Host Third Quarter 2022 Earnings Conference Call and Business Update

November 04, 2022

From Navidea Biopharmaceuticals, Inc.

Via Business Wire

Navidea Biopharmaceuticals Announces Acceptance of Abstract for Presentation at Upcoming Society for Immunotherapy of Cancer Annual Meeting

October 05, 2022

From Navidea Biopharmaceuticals, Inc.

Via Business Wire

Navidea Biopharmaceuticals Appoints Joshua Wilson to the Board of Directors; Announces Dates Related to its 2022 Annual Meeting of Stockholders

September 30, 2022

From Navidea Biopharmaceuticals, Inc.

Via Business Wire

Why ZW Data Action Technologies Jumped 37%; Here Are 71 Biggest Movers From Yesterday ↗

September 16, 2022

Gainers

Via Benzinga

Navidea Biopharmaceuticals Announces Presentation of Results from its Two Phase 2B Clinical Trials in Rheumatoid Arthritis at Upcoming American College of Rheumatology Annual Meeting

September 15, 2022

From Navidea Biopharmaceuticals, Inc.

Via Business Wire

Why Adobe Is Trading Lower By 17%, Here Are 49 Stocks Moving In Thursday's Mid-Day Session ↗

September 15, 2022

Gainers HeartBeam, Inc. (NASDAQ: BEAT) shares surged 58% to $1.96 after the company announced its patent for a 12-lead electrocardiogram patch monitor intended for detection of acute coronary syndrome...

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday ↗

September 14, 2022

We're starting off Wednesday with an overview of the biggest pre-market stock movers this morning and the news moving those shares!

Via InvestorPlace

Why Kaspien Holdings Is Trading Lower By 13%; Here Are 21 Stocks Moving Premarket ↗

September 14, 2022

Gainers Aditxt, Inc. (NASDAQ: ADTX) rose 54.3% to $28.56 in pre-market trading following effect of 1:50 reverse stock split.

Via Benzinga

Navidea Biopharmaceuticals Announces Opening of Nine New Sites in its Pivotal Phase 3 Trial in Rheumatoid Arthritis and Termination of Binding Memorandum of Understanding with Jubilant Radiopharma

September 01, 2022

From Navidea Biopharmaceuticals, Inc.

Via Business Wire

Navidea Biopharmaceuticals Announces Oral Ruling in Case Involving Attorney’s Fees

September 01, 2022

From Navidea Biopharmaceuticals, Inc.

Via Business Wire

Navidea Biopharmaceuticals Announces Closing of its Rights Offering and Second Quarter 2022 Earnings Conference Call and Business Update

August 30, 2022

From Navidea Biopharmaceuticals, Inc.

Via Business Wire

Navidea Biopharmaceuticals Announces Subscriptions of Approximately $14.2 Million from its Rights Offering

August 25, 2022

From Navidea Biopharmaceuticals, Inc.

Via Business Wire

Short Volatility Alert: Navidea Biopharmaceuticals, Inc. ↗

August 24, 2022

On Tuesday, shares of Navidea Biopharmaceuticals, Inc. (NYSE: NAVB) experienced volatile short activity. After the activity, the stock price went up +0.00% to $0.39. The overall sentiment for NAVB has...

Via Benzinga

Navidea Biopharmaceuticals Announces Extension of Subscription Period to August 24, 2022 and Updated Terms of its Previously Announced Rights Offering

August 18, 2022

From Navidea Biopharmaceuticals, Inc.

Via Business Wire

Stocks That Hit 52-Week Lows On Thursday ↗

August 18, 2022

During Thursday's trading, 62 companies set new 52-week lows.

Via Benzinga

Stocks That Hit 52-Week Lows On Tuesday ↗

August 16, 2022

On Tuesday, 37 stocks hit new 52-week lows.

Via Benzinga

Navidea Biopharmaceuticals Reports Second Quarter 2022 Financial Results

August 15, 2022

From Navidea Biopharmaceuticals, Inc.

Via Business Wire

Navidea Biopharmaceuticals Announces Commencement of Rights Offering Subscription Period and Updated Terms of its Previously Announced Rights Offering

August 04, 2022

From Navidea Biopharmaceuticals, Inc.

Via Business Wire

Navidea Biopharmaceuticals Announces Publication of Study Examining Use of Tc99m Tilmanocept for Lymphatic Mapping and Sentinel Lymph Node Biopsy in Melanoma and Oral Cancer in Australia

August 01, 2022

From Navidea Biopharmaceuticals, Inc.

Via Business Wire

Navidea Biopharmaceuticals Reminds Investors of Today’s Deadline to be a Shareholder of Record for the Previously Announced Rights Offering

August 01, 2022

From Navidea Biopharmaceuticals, Inc.

Via Business Wire

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.